Does the media prefer OLMA or OGN?

In the previous week, Organon & Co. had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Organon & Co. and 1 mentions for Olema Pharmaceuticals. Organon & Co.'s average media sentiment score of 0.32 beat Olema Pharmaceuticals' score of -1.57 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, OLMA or DYN?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is OLMA or DYN more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Dyne Therapeutics N/A -58.28% -46.77%

Does the media prefer OLMA or DYN?

In the previous week, Dyne Therapeutics had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for Olema Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.61 beat Olema Pharmaceuticals' score of -1.57 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative Dyne Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RCUS or OLMA?

In the previous week, Arcus Biosciences and Arcus Biosciences both had 1 articles in the media. Arcus Biosciences' average media sentiment score of 1.71 beat Olema Pharmaceuticals' score of -1.57 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Which has preferable valuation & earnings, OLMA or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A Telix Pharmaceuticals $803.79M 4.31 -$7.12M N/A N/A

Is OLMA or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Telix Pharmaceuticals N/A N/A N/A

Does the media refer more to OLMA or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for Olema Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.44 beat Olema Pharmaceuticals' score of -1.57 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Olema Pharmaceuticals (OLMA) Competitors

$10.53 +0.53 (+5.30%)

As of 06/23/2026 04:00 PM Eastern

Compare

OLMA vs. NAMS, OGN, DYN, RCUS, and TLX

Should you buy Olema Pharmaceuticals stock or one of its competitors? MarketBeat compares Olema Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Olema Pharmaceuticals include NewAmsterdam Pharma (NAMS), Organon & Co. (OGN), Dyne Therapeutics (DYN), Arcus Biosciences (RCUS), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Olema Pharmaceuticals has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	163.14	-$203.82M	-$1.79	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

NewAmsterdam Pharma presently has a consensus target price of $48.60, suggesting a potential upside of 54.78%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 318.80%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.00 beat Olema Pharmaceuticals' score of -1.57 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
Olema Pharmaceuticals	Very Negative

NewAmsterdam Pharma has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Summary

NewAmsterdam Pharma and Olema Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Organon & Co.?

Olema Pharmaceuticals (NASDAQ:OLMA) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Olema Pharmaceuticals currently has a consensus target price of $44.10, indicating a potential upside of 318.80%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 15.24%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Organon & Co.	$6.16B	0.57	$187M	$0.93	14.46

Organon & Co. has a net margin of 3.99% compared to Olema Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Organon & Co.	3.99%	99.95%	6.22%

Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

In the previous week, Organon & Co. had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Organon & Co. and 1 mentions for Olema Pharmaceuticals. Organon & Co.'s average media sentiment score of 0.32 beat Olema Pharmaceuticals' score of -1.57 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Organon & Co. beats Olema Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Dyne Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Olema Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

In the previous week, Dyne Therapeutics had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for Olema Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.61 beat Olema Pharmaceuticals' score of -1.57 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Dyne Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Olema Pharmaceuticals' return on equity of -46.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 318.80%. Dyne Therapeutics has a consensus price target of $33.85, indicating a potential upside of 67.06%. Given Olema Pharmaceuticals' higher possible upside, research analysts plainly believe Olema Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

Summary

Olema Pharmaceuticals beats Dyne Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Arcus Biosciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Olema Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Olema Pharmaceuticals' return on equity of -46.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Olema Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

In the previous week, Arcus Biosciences and Arcus Biosciences both had 1 articles in the media. Arcus Biosciences' average media sentiment score of 1.71 beat Olema Pharmaceuticals' score of -1.57 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Arcus Biosciences currently has a consensus target price of $35.10, indicating a potential upside of 24.64%. Olema Pharmaceuticals has a consensus target price of $44.10, indicating a potential upside of 318.80%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Olema Pharmaceuticals beats Arcus Biosciences on 10 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Telix Pharmaceuticals	$803.79M	4.31	-$7.12M	N/A	N/A

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 318.80%. Telix Pharmaceuticals has a consensus price target of $21.13, indicating a potential upside of 106.90%. Given Olema Pharmaceuticals' higher probable upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for Olema Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.44 beat Olema Pharmaceuticals' score of -1.57 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats Olema Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$873.47M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-5.21	19.75	24.92	23.98
Price / Sales	N/A	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.79	8.29	10.79	6.50
Net Income	-$162.45M	$23.85M	$3.56B	$336.88M
7 Day Performance	11.55%	2.87%	1.00%	-0.14%
1 Month Performance	-23.03%	2.19%	0.42%	0.77%
1 Year Performance	124.52%	55.48%	29.70%	28.49%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	1.9049 of 5 stars	$10.53 +5.3%	$44.10 +318.8%	+151.3%	$873.47M	N/A	N/A	70
NAMS NewAmsterdam Pharma	2.0301 of 5 stars	$30.67 -0.5%	$48.60 +58.5%	+72.4%	$3.59B	$22.50M	N/A	4
OGN Organon & Co.	2.6601 of 5 stars	$13.44 +0.3%	$11.40 -15.1%	+37.0%	$3.53B	$6.22B	14.45	10,000	News Coverage
DYN Dyne Therapeutics	2.6044 of 5 stars	$20.99 +0.6%	$33.85 +61.2%	+99.4%	$3.48B	N/A	N/A	100	Analyst Upgrade Gap Down
RCUS Arcus Biosciences	3.3554 of 5 stars	$27.59 +1.3%	$35.10 +27.2%	+225.7%	$3.47B	$247M	N/A	500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. NAMS, OGN, DYN, RCUS, and TLX

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Olema Pharmaceuticals compare to Organon & Co.?

Summary

How does Olema Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Summary

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. NAMS, OGN, DYN, RCUS, and TLX

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Which has higher earnings and valuation, NAMS or OLMA?

Is NAMS or OLMA more profitable?

Do analysts recommend NAMS or OLMA?

Do institutionals and insiders hold more shares of NAMS or OLMA?

Does the media favor NAMS or OLMA?

Which has more risk & volatility, NAMS or OLMA?

Summary

How does Olema Pharmaceuticals compare to Organon & Co.?

Do insiders & institutionals believe in OLMA or OGN?

Do analysts recommend OLMA or OGN?

Which has higher valuation & earnings, OLMA or OGN?

Is OLMA or OGN more profitable?

Which has more volatility and risk, OLMA or OGN?

Does the media prefer OLMA or OGN?

Summary

How does Olema Pharmaceuticals compare to Dyne Therapeutics?

Which has more risk & volatility, OLMA or DYN?

Which has preferable earnings and valuation, OLMA or DYN?

Does the media prefer OLMA or DYN?

Do institutionals and insiders believe in OLMA or DYN?

Is OLMA or DYN more profitable?

Do analysts prefer OLMA or DYN?

Summary

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Which has more volatility & risk, RCUS or OLMA?

Do institutionals & insiders believe in RCUS or OLMA?

Is RCUS or OLMA more profitable?

Which has higher earnings & valuation, RCUS or OLMA?

Does the media favor RCUS or OLMA?

Do analysts prefer RCUS or OLMA?

Summary

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Which has more volatility and risk, OLMA or TLX?

Is OLMA or TLX more profitable?

Which has preferable valuation & earnings, OLMA or TLX?

Do analysts prefer OLMA or TLX?

Do insiders & institutionals have more ownership in OLMA or TLX?

Does the media refer more to OLMA or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools